|
TEVA OPPOSES 10-YEAR DATA EXCLUSIVITY PROVISION FOR ISRAEL
Israeli generic firm Teva Pharmaceutical is objecting to what it contends is pressure from U.S. trade officials that Israel adopt a 10-year data exclusivity period for drugs — a period twice as long as the exclusivity period in the U.S. This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives